Table 3 Correlation between snoRNA expression in FFPE and clinicopathologic characteristics of RCC patients
From: A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma
Characteristics | Cases | SNORD15A | SNORD35B | SNORD60 | |
|---|---|---|---|---|---|
P Value | P Value | P Value | |||
Gender | Male | 20 | 0.6442 | 0.7683 | 0.7851 |
Female | 16 | ||||
Age | >=50 | 27 | 0.5284 | 0.5653 | 0.1932 |
< 50 | 9 | ||||
T stage | T1 | 6 | 0.7391 | 0.2409 | 0.3939 |
T2 | 10 | ||||
T3 | 11 | ||||
T4 | 9 | ||||
Lymph node metastasis | N0 | 21 | 0.7559 | 0.8559 | 0.8262 |
N1 | 15 | ||||
Distant metastasis | M0 | 35 | -- | -- | -- |
M1 | 1 | ||||
TNM stage | I | 13 | 0.4363 | 0.0086* | 0.7427 |
II | 9 | ||||
III | 13 | ||||
IV | 1 | ||||
Grade | G1G2 | 24 | 0.5282 | 0.9200 | 0.4453 |
G3G4 | 9 | ||||
Not Available | 3 | ||||